DDIT3 and pneumocystosis: Three trials [10,17,20] that represented the occurrence of PCP in patients received R-CHOP tri-weekly (R-CHOP-21) and bi-weekly (R-CHOP-14) were included to assess the affect of different chemo-regimens and intervals on PCP risk.